What does this research mean for the field?

The CHA₂DS₂-VA score predicts 1-year mortality in COVID-19 patients, identifying those at higher risk of poor outcomes. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To investigate the predictive ability of the CHA2DS2-VA score for mortality and ICU admission in COVID-19 patients.

January 10, 2026BMC Cardiovascular Disorders0 citationsOpen Access

Impact of CHA₂DS₂-VA score on COVID-19 disease-related outcomes

GAGamze Yeter ArslanAntalya Eğitim ve Araştırma Hastanesi MOMetin Okşul YŞYusuf Ziya ŞenerCardio-Oncology

Key Result

The CHA₂DS₂-VA score predicts 1-year mortality in COVID-19 patients, identifying those at higher risk of poor outcomes.

Key Points

To investigate the predictive ability of the CHA2DS2-VA score for mortality and ICU admission in COVID-19 patients.
Screened COVID-19 patients diagnosed between January 2021 and January 2022.
Enrolled 838 patients with accessible data.
Recorded baseline characteristics and CHA2DS2-VA scores.
Analyzed relationships between scores and outcomes using statistical tests.
Mean age of participants was 53.8 years, with 53.6% male.
ICU admission occurred in 177 (21.1%) patients.
1-year mortality rate was 10.3%, with 86 patients deceased.
CHA2DS2-VA score was identified as an independent predictor of mortality.

Structured PICO

Does the CHA₂DS₂-VA score predict 1-year mortality and ICU admission in patients with COVID-19?

Population

838 patients diagnosed with COVID-19 between January 2021 and January 2022, mean age 53.8 ± 18.5 years, 53.6% male.

Intervention

CHA₂DS₂-VA score assessment

Outcome

1-year mortality and intensive care unit (ICU) admissionhard clinical

The simplified CHA₂DS₂-VA score, which excludes the sex factor, is an independent predictor of 1-year mortality and ICU admission in patients with COVID-19.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

OBJECTIVE: The Coronavirus disease (COVID-19) pandemic affected millions of people worldwide and caused hundreds of thousands of deaths. The CHA₂DS₂-VASc score is a scoring system used to determine the indication for anticoagulation in patients with atrial fibrillation (AF) and determines the risk of stroke. Previous studies have shown that it predicts mortality in COVID-19 patients well. New guidelines simplified the score as the CHA₂DS₂-VA score, which is free of sex factor. In this study, we planned to investigate the ability of this simplified score in predicting mortality and intensive care unit (ICU) admission in COVID-19 patients. MATERIALS AND METHODS: All patients who were diagnosed with COVID-19 between January 2021 and January 2022 were screened, and patients with accessible data were enrolled. A total of 838 patients were included. The baseline characteristics of the patients and CHA₂DS₂-VA scores were recorded, and their relationship with poor outcomes was investigated. Mann-Whitney U and T-test were used for continuous variables, while logistic regression and ROC analysis were performed to identify predictors of 1-year mortality and ICU admission. RESULTS: The mean age of the study population was 53.8 ± 18.5, and 53.6% of them (n = 449) were male. Intensive care unit (ICU) admission was present in 177 (21.1%) patients. 1-year mortality was present in 86 (10.3%) patients. Univariable regression analysis revealed that hypertension, diabetes mellitus, coronary artery disease, heart failure, atrial fibrillation, COPD, CHA CONCLUSIONS: As a result of our study, we found that the CHA₂DS₂-VA score is an independent predictor of 1-year mortality following COVID-19 disease. Cut-off values of the CHA

Ask AI

Helpful

Bookmark

View Full Paper